Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study-Reference-Cited by-同舟云学术

Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study

Published:2020-06-03 Issue:9 Volume:22 Page:1607-1618
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Birkeland Kåre I.¹^ORCID,Bodegard Johan²^ORCID,Eriksson Jan W.³^ORCID,Norhammar Anna⁴,Haller Hermann⁵,Linssen Gerard C.M.⁶,Banerjee Amitava⁷⁸,Thuresson Marcus⁹,Okami Suguru¹⁰^ORCID,Garal‐Pantaler Elena¹¹,Overbeek Jetty¹²^ORCID,Mamza Jil Billy¹³,Zhang Ruiqi¹³,Yajima Toshitaka¹⁰,Komuro Issei¹⁴,Kadowaki Takashi¹⁵¹⁶

Affiliation:

1. Oslo University Hospital and University of Oslo Oslo Norway

2. AstraZeneca Oslo Norway

3. Department of Medical Sciences, Clinical Diabetes and MetabolismUppsala University Uppsala Sweden

4. Cardiology Unit, Department of Medicine, SolnaKarolinska Institute, Stockholm, Sweden and Capio S:t Görans Hospital Stockholm Sweden

5. Division of NephrologyHannover Medical School Hannover Germany

6. Department of CardiologyHospital Group Twente Hengelo The Netherlands

7. Institute of Health InformaticsUniversity College London London UK

8. Department of CardiologyUniversity College London Hospitals London UK

9. Statisticon AB Uppsala Sweden

10. AstraZeneca Osaka Japan

11. Team Gesundheit GmbH Essen Germany

12. PHARMO Institute for Drug Outcomes Research CRS Utrecht The Netherlands

13. AstraZeneca Luton UK

14. Department of Cardiovascular Medicine, Graduate School of MedicineUniversity of Tokyo Tokyo Japan

15. Department of Prevention of Diabetes and Lifestyle‐Related Diseases, Graduate School of MedicineUniversity of Tokyo Tokyo Japan

16. Department of Metabolism and Nutrition, Mizonokuchi HospitalTeikyo University Kanagawa Japan

Funder

AstraZeneca

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14074

Reference61 articles.

1. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study;Birkeland KI;Diabetes Obes Metab,2018

2. The Association Between Glucose Abnormalities and Heart Failure in the Population-Based Reykjavík Study

3. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

4. Diabetes, heart failure, and renal dysfunction: The vicious circles

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of finerenone in diabetic kidney disease patients: a real-world observational study from China;Renal Failure;2024-09-09

2. Use of, time to, and type of first add‐on anti‐hyperglycaemic therapy to metformin in Australia, 2018–2022;British Journal of Clinical Pharmacology;2024-09-03

3. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial;Journal of the American College of Cardiology;2024-08

4. What is the best predictor of mortality in patients with type 2 diabetes and chronic kidney disease: mean, variability of HbA1c or HbA1c-Hemoglobin ratio?;BMC Nephrology;2024-07-31

5. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis;The Lancet Diabetes & Endocrinology;2024-07